LWLuisa Weisskoeppel
Luisa Weisskoeppel
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luisa Weisskoeppel has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anton Selich
Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
1 shared publication - Antonella Lucia Bastone
Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
1 shared publication - Axel Schambach
Hannover Medical School
1 shared publication - Dirk Schaudien
Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
1 shared publication - Jenni Fleischauer
Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
1 shared publication - Michael Rothe
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany
1 shared publication
Latest Publications
- Open Access
TGFβ Inhibitor A83-01 Enhances Murine HSPC Expansion for Gene Therapy
Murine hematopoietic stem and progenitor cells (HSPCs) are commonly used as model systems during gene therapeutic retroviral vector development and preclinical biosafety assessment. Here, we developed cell culture conditions to maintain stemness and prevent differentiation during HSPC culture. We used the small compounds A83-01, pomalidomide, and UM171 (APU). Highly purified LSK SLAM cells expanded in medium containing SCF, IL-3, FLT3-L, and IL-11 but rapidly differentiated to myeloid progenitors and mast cells. The supplementation of APU attenuated the differentiation and preserved the stemness of HSPCs. The TGF inhibitor A83-01 was identified as the major effector. It significantly inhibited the mast-cell-associated expression of FcR1 and the transcription of genes regulating the formation of granules and promoted a 3800-fold expansion of LSK cells. As a functional readout, we used expanded HSPCs in state-of-the-art genotoxicity assays. Like fresh cells, APU-expanded HSPCs transduced with a mutagenic retroviral vector developed a myeloid differentiation block with clonal restriction and dysregulated oncogenic transcriptomic signatures due to vector integration near the high-risk locus Mecom. Thus, expanded HSPCs might serve as a novel cell source for retroviral vector testing and genotoxicity studies.Open AccessTGFβ Inhibitor A83-01 Enhances Murine HSPC Expansion for Gene Therapy
Murine hematopoietic stem and progenitor cells (HSPCs) are commonly used as model systems during gene therapeutic retroviral vector development and preclinical biosafety assessment. Here, we developed cell culture conditions to maintain stemness and prevent differentiation during HSPC culture. We used the small compounds A83-01, pomalidomide, and UM171 (APU). Highly purified LSK SLAM cells expanded in medium containing SCF, IL-3, FLT3-L, and IL-11 but rapidly differentiated to myeloid progenitors and mast cells. The supplementation of APU attenuated the differentiation and preserved the stemness of HSPCs. The TGF inhibitor A83-01 was identified as the major effector. It significantly inhibited the mast-cell-associated expression of FcR1 and the transcription of genes regulating the formation of granules and promoted a 3800-fold expansion of LSK cells. As a functional readout, we used expanded HSPCs in state-of-the-art genotoxicity assays. Like fresh cells, APU-expanded HSPCs transduced with a mutagenic retroviral vector developed a myeloid differentiation block with clonal restriction and dysregulated oncogenic transcriptomic signatures due to vector integration near the high-risk locus Mecom. Thus, expanded HSPCs might serve as a novel cell source for retroviral vector testing and genotoxicity studies.